MX2023004794A - Uso de un anticuerpo de anticumulo de diferenciacion 19 (anti-cd19) para tratar enfermedades autoinmunitarias. - Google Patents

Uso de un anticuerpo de anticumulo de diferenciacion 19 (anti-cd19) para tratar enfermedades autoinmunitarias.

Info

Publication number
MX2023004794A
MX2023004794A MX2023004794A MX2023004794A MX2023004794A MX 2023004794 A MX2023004794 A MX 2023004794A MX 2023004794 A MX2023004794 A MX 2023004794A MX 2023004794 A MX2023004794 A MX 2023004794A MX 2023004794 A MX2023004794 A MX 2023004794A
Authority
MX
Mexico
Prior art keywords
antibody
autoimmune disease
treat autoimmune
treat
vib551
Prior art date
Application number
MX2023004794A
Other languages
English (en)
Spanish (es)
Inventor
William Rees
Eliezer Katz
Dewei She
John Ratchford
Li Yan
Original Assignee
Viela Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viela Bio Inc filed Critical Viela Bio Inc
Publication of MX2023004794A publication Critical patent/MX2023004794A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2023004794A 2020-10-29 2021-10-29 Uso de un anticuerpo de anticumulo de diferenciacion 19 (anti-cd19) para tratar enfermedades autoinmunitarias. MX2023004794A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063107182P 2020-10-29 2020-10-29
US202163143541P 2021-01-29 2021-01-29
US202163178286P 2021-04-22 2021-04-22
PCT/US2021/057443 WO2022094334A1 (en) 2020-10-29 2021-10-29 Use of an anti-cd19 antibody to treat autoimmune disease

Publications (1)

Publication Number Publication Date
MX2023004794A true MX2023004794A (es) 2023-09-15

Family

ID=81384348

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004794A MX2023004794A (es) 2020-10-29 2021-10-29 Uso de un anticuerpo de anticumulo de diferenciacion 19 (anti-cd19) para tratar enfermedades autoinmunitarias.

Country Status (10)

Country Link
US (1) US20230287114A1 (cg-RX-API-DMAC10.html)
EP (1) EP4237447A4 (cg-RX-API-DMAC10.html)
JP (2) JP7900888B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230097118A (cg-RX-API-DMAC10.html)
AU (1) AU2021368769A1 (cg-RX-API-DMAC10.html)
CA (1) CA3197022A1 (cg-RX-API-DMAC10.html)
IL (1) IL302294A (cg-RX-API-DMAC10.html)
MX (1) MX2023004794A (cg-RX-API-DMAC10.html)
TW (1) TW202233676A (cg-RX-API-DMAC10.html)
WO (1) WO2022094334A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023534916A (ja) * 2020-06-30 2023-08-15 ビエラ バイオ インコーポレイテッド 視神経脊髄炎スペクトラム障害を治療する方法
WO2025202213A1 (en) 2024-03-26 2025-10-02 Institut National de la Santé et de la Recherche Médicale Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
EP3959241A4 (en) * 2019-04-24 2023-01-25 Viela Bio, Inc. USE OF AN ANTI-CD19 ANTIBODY TO TREAT AN AUTOIMMUNE DISEASE
JP2023534916A (ja) * 2020-06-30 2023-08-15 ビエラ バイオ インコーポレイテッド 視神経脊髄炎スペクトラム障害を治療する方法

Also Published As

Publication number Publication date
TW202233676A (zh) 2022-09-01
AU2021368769A1 (en) 2023-06-08
WO2022094334A1 (en) 2022-05-05
IL302294A (en) 2023-06-01
KR20230097118A (ko) 2023-06-30
JP2026120679A (ja) 2026-07-22
CA3197022A1 (en) 2022-05-05
JP7900888B2 (ja) 2026-08-05
US20230287114A1 (en) 2023-09-14
JP2023549075A (ja) 2023-11-22
EP4237447A4 (en) 2024-07-17
AU2021368769A9 (en) 2024-05-30
EP4237447A1 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
WO2020219743A3 (en) Use of an anti-cd19 antibody to treat autoimmune disease
MX2025000067A (es) Anticuerpo anti glicoproteina de transmembrana mucina-1 (muc1)
EA200970556A1 (ru) Моноклональные антитела против angptl3
MX2022015133A (es) Anticuerpo humanizado anti-receptor de igf-1.
CO2021009693A2 (es) Proteínas de unión a antígeno del receptor gamma anti-il2
ES2523194T3 (es) Anticuerpo monoclonal humano específico para cada tumor
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
PE20100251A1 (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
JOP20190002A1 (ar) أجسام مضادة (أنتي – بي دي – 1) وطريقة الإنتاج وطريقة استخدام كل منهم
MX2010007935A (es) Anticuerpo monoclonal humanizado anti-nkg2a humano.
BR112021020532A2 (pt) Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3
MX2022005949A (es) Anticuerpos anti-ror-2 y metodos de uso.
PH12020551187A1 (en) Bispecific antigen-binding molecules and methods of use
NO20076568L (no) Anti-IL2 antistoffer
EA200701452A1 (ru) Моноклональные антитела против подобного ангиопоэтину белка 4 (angptl 4)
JOP20210169A1 (ar) أجسام مضادة أحادية النسيلة ضد منطقة سلسلة بيتا من trbv9 بشري
WO2021203030A3 (en) Methods of use of anti-trem2 antibodies
WO2020247929A8 (en) High affinity anti-cd3 antibodies, and methods for their generation and use
MX2021015882A (es) Fragmentos de unión a antígeno egfr y composiciones que los comprenden.
PH12022552725A1 (en) Anti-ox40 antibody and uses thereof
MY206214A (en) Monoclonal antibodies that bind specifically to human trbv9
WO2022174103A3 (en) Monoclonal antibodies specific for human ror1
CR20210467A (es) Tratamiento de cáncer con anticuerpos biespecíficos contra her2xcd3 en combinación con mab anti-her2
MX2023004275A (es) Anticuerpos biespecificos anti-pd-1/cd40 y usos de los mismos.
MX2022008421A (es) Anticuerpo anti-galectina-9 y usos del mismo.